[123I]FP-CIT-SPECT asymmetry index to differentiate Parkinson’s disease from vascular parkinsonism

Contrafatto, Donatella; Mostile, Giovanni; Nicoletti, Alessandra; Dibilio, Valeria; Raciti, Loredana; Lanzafame, Salvatore; Luca, Antonina; Distefano, Angela; Zappia, Mario

doi:10.1111/j.1600-0404.2011.01583.x

Cited by 48 publications

(36 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, Zijlmans et al 32 also described that dopaminergic deficit in patients with VP can sometimes be as marked as in patients with PD. Contrafatto et al 33 recently reported that the striatal asymmetry index is usually significantly higher in PD compared with VP, although occasionally, high asymmetry in bilateral uptake ratios can be found in these patients 32. In our study, we also found higher caudate and putamen uptake and higher putamen/caudate ratio in patients with VP compared with those with PD.…”

Section: Discussionsupporting

confidence: 73%

Clinical features and¹²³I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease

Benítez-Rivero

Marín-Oyaga

García-Solís

et al. 2012

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 73%

Clinical features and¹²³I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease

Benítez-Rivero

Marín-Oyaga

García-Solís

et al. 2012

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

show abstract

“…Contrafotto et al analyzed the striatal asymmetry index of DAT binding in patients with vascular PS, PD, and ET. On observing that the index was significantly lower in vascular PS than in PD subjects, the authors suggested that this parameter may be used for differentiating vascular PS from PD with a good degree of certainty (58).…”

Section: Vascular Psmentioning

confidence: 99%

Nigrostriatal Dopamine Terminal Imaging with Dopamine Transporter SPECT: An Update

2013

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the radiopharmaceuticals used to evaluate nigrostriatal dopamine imaging; (2) the pattern of uptake of these radiopharmaceuticals in parkinsonian syndromes; and (3) the role of these radiopharmaceuticals in the evaluation of parkinsonian syndromes.Financial Disclosure: Dr. Tatsch is a meeting participant/lecturer for GE Healthcare. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, participants can access this activity through the SNMMI Web site (http:// www.snmmi.org/ce_online) through August 2016.This article gives an update on nigrostriatal dopamine terminal imaging, with emphasis on SPECT performed with the presynaptic dopamine transporter (DAT) ligand 123 I-FP-CIT. The paper covers the rational use of this technique in the diagnostic work-up of patients with known or suspected parkinsonian syndromes. In detail, it addresses the impact of the method for the proof or exclusion of neurodegenerative parkinsonism, for its early and preclinical diagnosis, and for the evaluation of disease progression. The importance of normal DAT binding for differentiating symptomatic parkinsonism and relevant tremor syndromes from neurodegeneration is highlighted. Particularly emphasized is the role of DAT SPECT for diagnosing Lewy body dementia and its separation from Alzheimer dementia. Finally, some remarks deal with the economic aspects of the use of these imaging techniques in the clinical setting.

show abstract

“…The outcome measures are usually the specific-to-nonspecific binding ratio which is calculated as (ROI-background)/background [12], and the right:left asymmetry index which is calculated as [(R−L)/(R+L)]×2×100, where R=striatum contralateral to the most affected side of the body, L=striatum, ipsilateral to the most affected side of the body [13]. A striatal-binding index can also be calculated as [(ROI caudate+ROI putamen)−background]/background [14].…”

Section: Interpretation Of 123 I Fp-cit Spect Scan Datamentioning

confidence: 99%

Overview of Dopamine Transporter Imaging in Parkinson’s Disease, Dementia with Lewy Bodies and Other Dementias

Malek

Grosset

2015

Curr Geri Rep

View full text Add to dashboard Cite

123 I FP-CIT is a radiotracer that is used in conjunction with single photon emission computed tomography (SPECT) scanning to detect dopaminergic neuron presynaptic terminal degeneration, in the striatum (caudate nucleus and putamen) of patients with Parkinson's disease (PD) and dementia with Lewy bodies (DLB), showing a reduced uptake of this ligand by the dopamine transporters (DaT). This is a licensed diagnostic test in Europe (as DaTSCAN) and in the USA (as DaTscan). Recent work on functional imaging in PD and DLB largely uses the FP-CIT SPECT approach, and this is the focus of our paper, whilst noting that other ligands (e.g. beta-CIT) and imaging techniques such as positron emission tomography (PET) have been used in similar settings.

show abstract

[123I]FP-CIT-SPECT asymmetry index to differentiate Parkinson’s disease from vascular parkinsonism

Abstract: SAI detected using [(123) I]FP-CIT SPECT can be used to differentiate VP and PD with a good degree of certainty.

Cited by 48 publications

References 13 publications

Clinical features and¹²³I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease

Clinical features and¹²³I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease

Nigrostriatal Dopamine Terminal Imaging with Dopamine Transporter SPECT: An Update

Overview of Dopamine Transporter Imaging in Parkinson’s Disease, Dementia with Lewy Bodies and Other Dementias

Contact Info

Product

Resources

About

[123I]FP-CIT-SPECT asymmetry index to differentiate Parkinson’s disease from vascular parkinsonism

Abstract: SAI detected using [(123) I]FP-CIT SPECT can be used to differentiate VP and PD with a good degree of certainty.

Cited by 48 publications

References 13 publications

Clinical features and123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease

Clinical features and123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease

Nigrostriatal Dopamine Terminal Imaging with Dopamine Transporter SPECT: An Update

Overview of Dopamine Transporter Imaging in Parkinson’s Disease, Dementia with Lewy Bodies and Other Dementias

Contact Info

Product

Resources

About

Clinical features and¹²³I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease

Clinical features and¹²³I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease